We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

134 hedge funds and large institutions have $270M invested in MoonLake Immunotherapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more call options, than puts

Call options by funds: $33.1M | Put options by funds: $14.4M

3% more funds holding

Funds holding: 130 → 134 (+4)

9% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 45

20% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 41

33.32% less ownership

Funds ownership: 92.59% → 59.27% (-33%)

83% less funds holding in top 10

Funds holding in top 10: 6 → 1 (-5)

90% less capital invested

Capital invested by funds: $2.77B → $270M (-$2.5B)

Holders
134
Holders Change
+4
Holders Change %
+3.08%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-83.33%
% of All Funds
0.01%
New
49
Increased
33
Reduced
41
Closed
45
Calls
$33.1M
Puts
$14.4M
Net Calls
+$18.7M
Net Calls Change
+$16.8M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$78.2M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$66.5M
3
SSA
Schonfeld Strategic Advisors
New York
+$50.3M
4
Two Sigma Investments
Two Sigma Investments
New York
+$23.7M
5
IC
Ikarian Capital
Texas
+$22.7M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$339M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$261M
3
ACA
Avoro Capital Advisors
New York
-$112M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$93.3M
5
Citadel Advisors
Citadel Advisors
Florida
-$84.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
126
Barclays
United Kingdom
$115 -$236K -4,537 -100%
AF
127
Allworth Financial
California
$115 -$1.77K -34 -68%
S
128
SignatureFD
Georgia
$79 – – –
EWA
129
EverSource Wealth Advisors
Alabama
$57 +$417 +8 New
MA
130
Montag & Associates
Georgia
$51 +$365 +7 New
GI
131
GAMMA Investing
California
$43 +$313 +6 New
TWD
132
True Wealth Design
Ohio
$36 – – –
WA
133
WPG Advisers
Maryland
$22 +$156 +3 New
TRCT
134
Tower Research Capital (TRC)
New York
$7 -$14.2K -273 -100%
Westfield Capital Management
135
Westfield Capital Management
Massachusetts
– -$59.4M -1,259,376 Closed
Federated Hermes
136
Federated Hermes
Pennsylvania
– -$58.9M -1,248,573 Closed
AllianceBernstein
137
AllianceBernstein
Tennessee
– -$53.7M -1,138,022 Closed
PBA
138
Paradigm Biocapital Advisors
New York
– -$41.5M -878,323 Closed
RI
139
RTW Investments
New York
– -$35M -741,090 Closed
HRCM
140
Hood River Capital Management
Florida
– -$31.9M -675,445 Closed
VPC
141
Vestal Point Capital
New York
– -$26M -550,000 Closed
SL
142
Siren LLC
Connecticut
– -$24M -508,267 Closed
MB
143
MPM BioImpact
Massachusetts
– -$14.8M -313,571 Closed
FAM
144
Fred Alger Management
New York
– -$14M -295,623 Closed
SVCM
145
Saturn V Capital Management
Texas
– -$13.7M -290,784 Closed
5VM
146
5AM Venture Management
California
– -$13.3M -282,313 Closed
PCH
147
Polar Capital Holdings
United Kingdom
– -$11.7M -247,500 Closed
VOYA Investment Management
148
VOYA Investment Management
Georgia
– -$11.6M -246,114 Closed
IHAM
149
Integral Health Asset Management
New York
– -$9.44M -200,000 Closed
LGM
150
Logos Global Management
California
– -$9.44M -200,000 Closed
4 5
6
7 8

MLTX Hedge Fund Activity: Q3 2025 in Review

134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2025, worth a combined $270M — down 90% from $2.77B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new MLTX positions and 45 closed out — a net gain of 4 holders — while 33 added to existing stakes and 41 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $78.2M. The largest seller was Cormorant Asset Management, cutting an estimated $339M.

  • 134 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2025, up from 130 in Q2 2025.
  • Funds reported $270M of MoonLake Immunotherapeutics stock for Q3 2025, down 90% quarter-over-quarter.
  • 49 funds opened new MoonLake Immunotherapeutics positions in Q3 2025 and 45 closed out, a net change of +4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q3 2025 was Adage Capital Partners, an estimated $78.2M added.
  • The largest MoonLake Immunotherapeutics seller in Q3 2025 was Cormorant Asset Management, an estimated $339M sold.

Based on aggregated 13F filings for Q3 2025.